Abstract

Evidence-based recommendations on fulvestrant (Faslodex) for treating locally advanced or metastatic (secondary), oestrogen-receptor positive breast cancer in postmenopausal women who have not had endocrine therapy before.

Guidance development process

How we develop NICE technology appraisal guidance

Next review: to be confirmed depending on the duration of further data collection.